{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ahn SH"],"funding":["The Bio &amp;amp; Medical Technology Development Program","The Basic Science Research Program"],"pagination":["E1835"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6073580"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(7)"],"pubmed_abstract":["Interleukin-1&beta; (IL-1&beta;) is a prominent pro-inflammatory cytokine that is implicated in a variety of autoimmune diseases and plays an important role in host defense against infections. IL-1&beta; activity increases with its increasing binding capacity to IL-1 receptors (IL-1Rs). Thus, numerous studies have targeted the discovery of molecules modulating the interactions between IL-1&beta; and IL-1R1. We have conducted an IL-1R1 structure-based virtual screening to identify small molecules that could alter IL-1&beta; activity, using in silico computational analysis. Sixty compounds from commercial libraries were predicted to bind to IL-1R1, and their influence on cytokine production in IL-1&beta;-stimulated gingival fibroblasts (GFs) was determined. Of these, only (2-(1,2-diphenyl-1H-indol-3-yl)ethanamine (DPIE) showed a synergistic increase in inflammatory molecules and cytokine production (IL-6, IL-8, and COX-2) at both mRNA and protein levels in IL-1&beta;-stimulated GFs. The enhancing activity of DPIE in IL-1&beta;-induced cytokine production increased in a dose-dependent manner without cytotoxicity. This pattern was also observed in IL-1&beta;-stimulated primary human periodontal ligament cells (PDLs). Furthermore, we measured the impact of DPIE on the IL-1&beta;⁻IL-1R1 system using surface plasmon resonance and demonstrated that DPIE increased the binding affinity of IL-1&beta; to IL-1R1. These data indicate that DPIE boosts IL-1&beta; signaling by enhancing the binding of IL-1&beta; to IL-1R1 in oral primary cells."],"journal":["International journal of molecular sciences"],"pubmed_title":["DPIE [2-(1,2-diphenyl-1H-indol-3-yl)ethanamine] Augments Pro-Inflammatory Cytokine Production in IL-1β-Stimulated Primary Human Oral Cells."],"pmcid":["PMC6073580"],"funding_grant_id":["2017R1A2B2005938","2016M3A9B6903087"],"pubmed_authors":["Chay KO","Lee S","Kim ND","Kim SH","Lee TH","Lee JK","Ahn SH","Jung S"],"additional_accession":[]},"is_claimable":false,"name":"DPIE [2-(1,2-diphenyl-1H-indol-3-yl)ethanamine] Augments Pro-Inflammatory Cytokine Production in IL-1β-Stimulated Primary Human Oral Cells.","description":"Interleukin-1&beta; (IL-1&beta;) is a prominent pro-inflammatory cytokine that is implicated in a variety of autoimmune diseases and plays an important role in host defense against infections. IL-1&beta; activity increases with its increasing binding capacity to IL-1 receptors (IL-1Rs). Thus, numerous studies have targeted the discovery of molecules modulating the interactions between IL-1&beta; and IL-1R1. We have conducted an IL-1R1 structure-based virtual screening to identify small molecules that could alter IL-1&beta; activity, using in silico computational analysis. Sixty compounds from commercial libraries were predicted to bind to IL-1R1, and their influence on cytokine production in IL-1&beta;-stimulated gingival fibroblasts (GFs) was determined. Of these, only (2-(1,2-diphenyl-1H-indol-3-yl)ethanamine (DPIE) showed a synergistic increase in inflammatory molecules and cytokine production (IL-6, IL-8, and COX-2) at both mRNA and protein levels in IL-1&beta;-stimulated GFs. The enhancing activity of DPIE in IL-1&beta;-induced cytokine production increased in a dose-dependent manner without cytotoxicity. This pattern was also observed in IL-1&beta;-stimulated primary human periodontal ligament cells (PDLs). Furthermore, we measured the impact of DPIE on the IL-1&beta;⁻IL-1R1 system using surface plasmon resonance and demonstrated that DPIE increased the binding affinity of IL-1&beta; to IL-1R1. These data indicate that DPIE boosts IL-1&beta; signaling by enhancing the binding of IL-1&beta; to IL-1R1 in oral primary cells.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jun","modification":"2026-04-08T00:51:35.351Z","creation":"2019-03-26T23:50:48Z"},"accession":"S-EPMC6073580","cross_references":{"pubmed":["29932110"],"doi":["10.3390/ijms19071835"]}}